Skip to main content
Premium Trial:

Request an Annual Quote

MBL Inks Pact with Envoy, Provides Access to RIP-Chip

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Medical & Biological Laboratories today announced it has signed a non-exclusive agreement with Envoy Therapeutics to provide it access to MBL's RIP-Chip technology.

Under the terms of the deal, MBL will receive an upfront payment of an undisclosed amount, annual licensing fees and potential milestone payments. Envoy will use the RIP-Chip for drug discovery and development.

Further terms of the deal were not disclosed.

MBL's RIP-Chip is for RNA-binding protein immunoprecipitation for microarray, sequencing, and PCR applications, according to the company's website. The technology is the only high-throughput approach for direct elucidation of complex molecular networks involving genes, DNA, RNA, microRNA, proteins, and RNA localization as mediated by specific binding proteins.

The importance of such networks has become increasingly evident with "the growing appreciation of RNAi therapy, drug discovery, and the role of RNA utilization in determining normal and disease outcomes," MBL said in a statement

MBL is based in Nagoya, Japan and develops solutions and clinical diagnostics. Envoy, headquartered in Jupiter, Fla., develops therapeutics with technology that combines genetic engineering with new molecular biology methods for labeling and extracting protein-making components of specific cell types.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.